Post
TC-110 by Adaptimmune Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
TC-110 is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
B-Vaxx by Imugene for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
B-Vaxx is under clinical development by Imugene and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive …
SLATE-001 by Gritstone Bio for Gastrointestinal Tumor: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Gastrointestinal Tumor. According to GlobalData, Phase …
SLATE-001 by Gritstone Bio for Metastatic Ovarian Cancer: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, …
SLATE-001 by Gritstone Bio for Metastatic Breast Cancer: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, …
Ftortiazinon by Gamaleya Federal Research Center of Epidemiology and Microbiology for Urinary Tract Infections: Likelihood of Approval
Ftortiazinon is under clinical development by Gamaleya Federal Research Center of Epidemiology and Microbiology and currently in Phase II for …
Rovadicitinib by Sino Biopharmaceutical for Hemophagocytic Lymphohistiocytosis: Likelihood of Approval
Rovadicitinib is under clinical development by Sino Biopharmaceutical and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase …
Monlunabant by Inversago Pharma for Obesity: Likelihood of Approval
Monlunabant is under clinical development by Inversago Pharma and currently in Phase II for Obesity. According to GlobalData, Phase II …
Monlunabant by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval
Monlunabant is under clinical development by Inversago Pharma and currently in Phase II for Metabolic Syndrome. According to GlobalData, Phase …
Supernitro by Attgeno for Pulmonary Embolism: Likelihood of Approval
Supernitro is under clinical development by Attgeno and currently in Phase I for Pulmonary Embolism. According to GlobalData, Phase I …
RiMO-401 by Coordination Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
RiMO-401 is under clinical development by Coordination Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell Carcinoma …
KPG-121 by Kangpu Biopharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
KPG-121 is under clinical development by Kangpu Biopharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According …
Gensci-059 by Changchun GeneScience Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Gensci-059 is under clinical development by Changchun GeneScience Pharmaceutical and currently in Phase I for Relapsed Acute Myeloid Leukemia. According …
YENEO-001 by NantBioScience for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
YENEO-001 is under clinical development by NantBioScience and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative …
YENEO-001 by NantBioScience for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
YENEO-001 is under clinical development by NantBioScience and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive …